VRD Cycle Counting in Multiple Myeloma
VRD cycles are counted every 3 weeks (21 days), with each cycle consisting of bortezomib on days 1,8, and 15; lenalidomide on days 1-14; and dexamethasone on the days of and after bortezomib administration. 1
Standard VRD Cycle Structure
According to ESMO guidelines, the VRD regimen follows this schedule 1:
- Bortezomib: 1.3 mg/m² subcutaneously on days 1,8, and 15
- Lenalidomide: 25 mg orally on days 1-14
- Dexamethasone: 20 mg on the day of and day after bortezomib (or alternatively 40 mg on days 1,8,15,22)
- Cycle length: Repeated every 3 weeks (21 days)
This means one complete cycle = 21 days, and you count a new cycle each time you restart this 3-week schedule.
Number of Cycles by Clinical Context
For Transplant-Eligible Patients (Induction)
4-6 cycles of VRD induction are recommended before proceeding to stem cell collection 1. The evidence supports:
- 4 cycles: Standard approach used in multiple trials 2, 3, 4
- 6 cycles: Alternative supported by PETHEMA/GEM2012 trial showing deepening responses (70.4% VGPR or better after 6 cycles vs 55.6% after 3 cycles) 4
For Transplant-Ineligible Patients
8 cycles of VRD followed by maintenance is the typical approach 5. After 8 cycles, patients may transition to:
- Maintenance schedule: once weekly bortezomib for 4 weeks (days 1,8,15,22) followed by 13-day rest (days 23-35) 5
- Or lenalidomide-based maintenance
For Extended/Maintenance Therapy
After completing initial cycles, maintenance dosing changes the cycle structure 5:
- Bortezomib: once weekly for 4 weeks (days 1,8,15,22)
- Rest period: 13 days (days 23-35)
- This creates 35-day maintenance cycles (not 21-day cycles)
Practical Cycle Counting Algorithm
- Start of Cycle 1: Day 1 when first bortezomib dose is given
- End of Cycle 1: Day 21 (includes 7-day rest period after day 14 lenalidomide)
- Start of Cycle 2: Day 22 (which becomes the new "day 1" of cycle 2)
- Continue counting: Each subsequent 21-day period = one additional cycle
Common Pitfalls to Avoid
Do not count cycles based on calendar months - VRD uses 21-day cycles, not monthly cycles. This differs from regimens like KRd or DRd which use 28-day cycles 1.
Do not restart cycle counting after dose modifications - If you reduce bortezomib from 1.3 mg/m² to 1.0 mg/m² or 0.7 mg/m² due to toxicity 5, you continue with the same cycle number, just at a reduced dose.
Account for treatment delays - If you hold doses due to toxicity (e.g., thrombocytopenia, neuropathy), the cycle number doesn't change until you complete that cycle's planned dosing and move to the next 21-day period 5.
Distinguish induction from maintenance cycles - After completing 8 induction cycles, if transitioning to maintenance, you may restart numbering as "maintenance cycle 1" since the schedule changes to 35-day cycles 5.
Dose Modifications Within Cycles
When toxicity occurs, hold or reduce doses but maintain the cycle structure 5:
- Grade 3-4 non-hematologic toxicity: Hold until resolved to grade 1, then resume at reduced dose (1.3→1.0→0.7 mg/m²)
- Peripheral neuropathy: Specific dose modification guidelines apply
- The 21-day cycle framework remains constant even with dose adjustments
The key principle: Each 21-day period from the start of bortezomib dosing = one cycle, regardless of dose modifications or brief treatment delays within that timeframe.